This article was originally published in The Gray Sheet
FDA urges hospital pharmacies and hemodialysis units to stop using the firm's triCitrasol, a 46.7% concentration of sodium citrate for use as a dialysis catheter anticoagulant, in an April 14 Talk Paper. The warning follows the death of a patient from a "full strength" injection of the unapproved product into a hemodialysis permanent blood access catheter that had just been implanted. The product "can cause fatal heart rhythm disruption, seizures or bleeding due to loss of blood calcium," according to FDA
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.